Oak Ridge Investments LLC Trims Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Oak Ridge Investments LLC reduced its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 30.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 86,342 shares of the company's stock after selling 37,464 shares during the period. Oak Ridge Investments LLC's holdings in Hims & Hers Health were worth $2,088,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. State Street Corp lifted its position in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after purchasing an additional 206,078 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after buying an additional 482,177 shares in the last quarter. Wellington Management Group LLP boosted its position in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after buying an additional 883,230 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company's stock valued at $30,714,000 after buying an additional 218,566 shares during the period. Finally, Verition Fund Management LLC grew its stake in Hims & Hers Health by 15.0% in the 3rd quarter. Verition Fund Management LLC now owns 645,731 shares of the company's stock worth $11,894,000 after acquiring an additional 84,316 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Price Performance

NYSE HIMS traded down $0.14 on Friday, hitting $27.80. The stock had a trading volume of 18,842,443 shares, compared to its average volume of 9,739,798. The business's fifty day moving average price is $27.68 and its 200 day moving average price is $21.86. The stock has a market cap of $6.07 billion, a price-to-earnings ratio of 63.19 and a beta of 1.31. Hims & Hers Health, Inc. has a 52-week low of $8.14 and a 52-week high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period in the previous year, the business earned ($0.04) EPS. The firm's revenue for the quarter was up 77.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the sale, the chief executive officer now owns 67,015 shares of the company's stock, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 17,304 shares of the business's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $22.00, for a total value of $380,688.00. Following the sale, the insider now owns 193,980 shares in the company, valued at approximately $4,267,560. The trade was a 8.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,080,208 shares of company stock worth $29,106,823 over the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

HIMS has been the subject of several research analyst reports. Morgan Stanley started coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They set an "overweight" rating and a $42.00 price target for the company. Piper Sandler upped their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a report on Monday, January 6th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Citigroup downgraded Hims & Hers Health from a "neutral" rating to a "sell" rating and lifted their price objective for the company from $24.00 to $25.00 in a report on Friday, January 10th. Finally, BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price on the stock. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.